A5067281862- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- HIV/AIDS drug development and treatment
- Systemic Lupus Erythematosus Research
- Hepatitis Viruses Studies and Epidemiology
- Chronic Lymphocytic Leukemia Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Diseases and Immunity
- Diabetes and associated disorders
- Diabetes Treatment and Management
- Drug-Induced Hepatotoxicity and Protection
- Viral gastroenteritis research and epidemiology
- Cytomegalovirus and herpesvirus research
- SARS-CoV-2 and COVID-19 Research
- Organ Transplantation Techniques and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer, Lipids, and Metabolism
- Gastrointestinal Bleeding Diagnosis and Treatment
- Animal Virus Infections Studies
- Bacteriophages and microbial interactions
- Pancreatitis Pathology and Treatment
- Atrial Fibrillation Management and Outcomes
- Blood groups and transfusion
University of Turin
2016-2025
Fondazione Ricerca Molinette
2011-2024
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2015-2024
University of Catania
2023
Ospedale Amedeo di Savoia
2022
Azienda Ospedaliero Universitaria San Giovanni Battista
2004-2019
Italian Medicines Agency
2018
University of Genoa
2013
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2013
Piedmont Reference Center for Epidemiology and Cancer Prevention
2013
Therapy of chronic hepatitis delta with standard interferon therapy has met limited efficacy. This study was designed to examine the efficacy and safety peginterferon or without ribavirin. Thirty-eight serum B surface antigen- HDV RNA-positive patients alanine aminotransferase (ALT) more than 1.5 times upper normal limit received alpha-2b (1.5 μg/kg) alone as monotherapy (n = 16) in combination ribavirin 22), for 48 weeks. Thereafter, all were maintained on 24 weeks followed off therapy. The...
Patients with hepatocellular carcinoma should be managed a multidisciplinary approach framed in network where all the diagnostic techniques and therapeutic resources are available order to provide optimal level of care. Given this assumption, Coordinating Committee Italian Association for Study Liver nominated panel experts elaborate practical recommendations management aiming provide: (1) homogeneous efficacious staging work-up, (2) best treatment choice tailored patient status tumour stage...
Abstract Background & Aims Hepatitis B virus ( HBV ) DNA integration in the host genome is a major mechanism responsible for etiopathogenetic role exerted by hepatocellular carcinoma HCC development. Extensive analyses evaluating viral surface antigen HB sAg) negative patients with occult infection OBI have not yet been performed. The aim of this study was to investigate and characterize tissues from patients. Methods Tumour extracts 69 (49 sAg‐negative diagnosed detection tumour...
Many studies showed insulin resistance amelioration in HCV-patients achieving Sustained Virologic Response (SVR) but results on glycemic control diabetic patients are unclear. This study aimed to assess fasting glucose (FG) and glycated hemoglobin (HbA1c) values before after therapy with direct-acting antivirals (DAAs) type 2 diabetes mellitus (T2DM). Of the 122 consecutively recruited chronic hepatitis C T2DM, 110 were treated DAAs 12 remained untreated. Clinical, biochemical, virological,...
Summary Background: Delta virus (HDV)‐related chronic hepatitis is difficult to treat. Aims: To evaluate the efficacy of lamivudine 100 mg daily on serum HDV‐RNA, D antibodies and alanine aminotransferase levels, liver histology, B surface antigen seroconversion. Methods: Thirty‐one antigen‐positive, HDV‐RNA‐positive patients with ALT ≥ 1.5 upper normal level compensated disease were randomized (1:2 ratio) placebo (group A, n = 11) or B, 20) for 52 weeks; thereafter, all given weeks followed...
BACKGROUND Patients with chronic hepatitis C are at risk of developing type 2 diabetes mellitus (DM) and impaired fasting glucose (IFG), this may increase among virus (HCV) patients not responding to an antiviral therapy. AIM To compare the incidence abnormalities (IFG or DM) after therapy between HCV+ a long-term virological response (LTR) nonresponders (NR; persistently positive HCV-RNA). METHODS All 202 without baseline enrolled by our center in investigational trials routinely treated...
Therapy of chronic hepatitis D with Interferon is successful when testing for HDV-RNA turns negative. This end-point disputed.To assess the role serum B surface antigen (HBsAg) in clearance pegylated interferon (Peg-IFN)-treated (CHD).Sixty-two patients CHD, treated Peg-IFN, were considered. The belonged to three groups: 14 cleared HBsAg and (responders, R), 12 remaining positive (partial responders, PR) 36 neither nor (nonresponders, NR).In at baseline median value (mv) was 1187 188 663...
Patients with hepatitis C virus (HCV)-related cirrhosis treated direct-acting antivirals (DAA) are still at risk of developing hepatocellular carcinoma (HCC). We investigated the accuracy non-invasive scoring systems (NSS) for prediction de novo HCC development in patients DAA on long-term follow-up (FU). analyzed data from 575 consecutive and no history who achieved a sustained virologic response (SVR) to therapy. NSS (i.e., Forns index, APRI, FIB-4, ALBI, aMAP) were calculated 3 months...
Background: The potential role of digestive endoscopy as a mode for transmission hepatitis C virus (HCV) is controversial. Objective: To evaluate the in transmitting HCV by comparing incidence infection cohort patients undergoing and blood donors. Design: Prospective study. Setting: 3 endoscopic units 2 banks northwestern Italy. Patients: potentially exposed consisted 9188 outpatients consecutively recruited from units. Of 9008 negative antibody to (anti-HCV), 8260 (92%) were retested...
Abstract Natural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort patients infected the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed 1445 HCV-infected DAA-naïve patients. Sanger-sequencing performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a 99 GT4d samples. Overall, 20.7% (301/1455) showed...
International guidelines recommend the use of ultrasound as a surveillance tool for hepatocellular carcinoma (HCC) in patients with cirrhosis, while role serum biomarkers is still debated. We investigated alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist II (PIVKA-II) and glypican-3 (GPC-3) diagnostic accuracy HCC detection prediction liver cirrhosis viral etiology under surveillance. A total 349 (200 149 HCC) were enrolled. The 200 consisted 114 HCC-free after 36...
Background and aims: The identification of patients with Hepatitis C Virus (HCV)-positive advanced chronic liver disease (aCLD) successfully treated by Direct Acting Antiviral Agents (DAAs) who really benefit from Hepatocellular Carcinoma (HCC) surveillance programs is still a matter debate. We performed long-term prospective cohort study on F3-F4 HCV-positive achieving Sustained Virologic Response (SVR) after DAAs treatment in order to identify can safely suspend surveillance. Methods: 1000...
Background and aimsSevere liver disease markers assessed before HCV eradication are acknowledged to usually improve after the SVR. We prospectively evaluated, in PITER cohort, long-term HCC risk profile based on predictors monitored by direct-acting antivirals patients with cirrhosis.MethodsHCC occurrence was evaluated Kaplan-Meier analysis. Cox regression analysis identified post-treatment variables associated de-novo HCC; their predictive power presented a nomogram.ResultsAfter end of...
The study measures trends in the profile of patients with chronic hepatitis B virus linked to care Italy.A cross-sectional, multicenter, observational cohort (PITER cohort) consecutive surface antigen (HBsAg) over period 2019-2021 from 46 centers was evaluated. reference MASTER collected years 2012-2015. Standard statistical methods were used.The PITER enrolled 4583 patients, whom 21.8% non-Italian natives. Compared those MASTER, older and more often female. prevalence e (HBeAg) declined...